Vehicle Safety
Recalls Search 320,000+ NHTSA safety recalls Complaints 2.1M+ consumer safety complaints TSBs 4.7M technical service bulletins VIN Lookup Decode any vehicle VIN instantly OBD Codes 12,000+ diagnostic trouble codes Fuel Economy EPA MPG data for all vehicles Statistics Recall trends & safety analysis
Consumer Safety
Product Safety 9,700+ CPSC product recalls Food Safety 28,600+ FDA food recalls Pet Safety 1.3M FDA animal adverse events Drug Safety 17,500+ FDA drug recalls Device Safety 38,400+ FDA device recalls Workplace Safety 102,900+ OSHA injury reports
Infrastructure
Bridge Safety 624,000 bridge inspections Aviation Safety 30,000+ NTSB aviation events Dam Safety 92,600 dam safety records Water Safety 433,000+ public water systems Railroad Safety 438,000+ rail crossings Pipeline Safety 8,800+ pipeline incidents
Public Health
Nursing Homes 14,700 CMS rated facilities Environmental 80,000+ hazardous sites & releases

Browse Drug Recalls

180 FDA drug safety recalls.

FDA Drug Recall Enforcement Database

Browse 180 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.

Drug Safety Recalls

Browse 180 FDA drug recalls in MD.

Clear
DateProductReasonClassFirm
Nov 21, 2017 Duloxetine Delayed-Release Capsules USP, 30 mg, 30-count bottles, Rx Only, Ma... Failed Dissolution Specification Class III Lupin Pharmaceuticals Inc.
Oct 30, 2017 Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only,... Marketed without an approved NDA/ANDA: Bottles were released prior to final approval. Class III Jubilant Cadista Pharmaceuticals, Inc.
Jun 22, 2017 Paroxetine Extended-Release Tablets USP, 12.5 mg, 30 count bottle, Rx only, M... Failed Dissolution Specifications: out of specification observed in dissolution testing at 3 mon... Class III Lupin Pharmaceuticals Inc.
Jun 1, 2017 methylcobalamin 1mg/1mL, vial for injection, Rx only, MedPark Pharmacy 2002 ... Lack of Assurance of Sterility Class II MedPark Pharmacy, LLC
May 2, 2017 Famotidine for Oral Suspension USP, 40 mg/5 mL, 50 mL bottle, Rx only, Manufa... CGMP Deviations Class III Lupin Pharmaceuticals Inc.
Jul 12, 2016 Trokendi XR (topiramate) extended-release capsule, 50mg, 30-count blister pac... Superpotent Drug: Failure of assay specifications in the capsule. Class II Supernus Pharmaceuticals, Inc.
Jun 13, 2016 Methylprednisolone Tablets, USP, 16 mg, 50-count bottles, Rx only, Manufactur... Labeling: Incorrect or Missing Lot and/or Exp Date: incorrect expiration date of 02/0218 is print... Class III Jubilant Cadista Pharmaceuticals, Inc.
Apr 8, 2016 BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, packaged ... Failed Impurities/Degradation Specifications: high out of specification results for one of the kn... Class III Jubilant Cadista Pharmaceuticals, Inc.
Apr 8, 2016 BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 100 mg, packaged ... Failed Impurities/Degradation Specifications: high out of specification results for one of the kn... Class III Jubilant Cadista Pharmaceuticals, Inc.
Apr 8, 2016 BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 150 mg, packaged ... Failed Impurities/Degradation Specifications: high out of specification results for one of the kn... Class III Jubilant Cadista Pharmaceuticals, Inc.
Apr 6, 2016 Lisinopril Tablets USP, 30 mg, packaged in a) 500-count bottles (NDC 68180-51... CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose int... Class III Lupin Pharmaceuticals Inc.
Apr 6, 2016 Lisinopril Tablets USP, 40 mg, 1000-count bottles, Rx only, Manufactured for:... CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose int... Class III Lupin Pharmaceuticals Inc.
Apr 4, 2016 Lisinopril & Hydrochlorothiazide Tables, USP 20mg/12.5mg, packaged in a)100-c... CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose int... Class III Lupin Pharmaceuticals Inc.
Mar 11, 2016 Ceftriaxone for Injection USP, 250 mg, Single Use Vial, packaged in a) 1-coun... CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose int... Class III Lupin Pharmaceuticals Inc.
Mar 11, 2016 Ceftriaxone Sodium (Sterile) USP active pharmaceutical ingredient, DMF No. 15... CGMP Deviations: active pharmaceutical ingredient intermediates failed specifications. Class III Lupin Pharmaceuticals Inc.
Mar 11, 2016 Ceftriaxone for Injection USP, 1 g, Single Use Vial (NDC 68180-633-01) packag... CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose int... Class III Lupin Pharmaceuticals Inc.
Mar 11, 2016 Ceftriaxone for Injection USP, 500 mg, Single Use Vial, packaged in a) 1-coun... CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose int... Class III Lupin Pharmaceuticals Inc.
Mar 11, 2016 Ceftriaxone for Injection USP, 2 g, Single Use Vial (NDC 68180-644-01) packag... CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose int... Class III Lupin Pharmaceuticals Inc.
Dec 7, 2015 Quinapril Tablets USP 5 mg, 90 count bottles, Lupin Pharmaceuticals, Inc., Ba... Failed Impurities/Degradation Specifications; Impurity A Class III Lupin Pharmaceuticals Inc.
Oct 5, 2015 NATUREAL BURN FAT NATURE, 30-count capsules, packaged in clear plastic bottle... Marketed Without an Approved NDA/ANDA: Product contains undeclared sibutramine. Class I Inaffit, LLC
Jul 11, 2014 Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, 90-tabl... Presence of Foreign Substance: Tablets may contain dark blemishes identified as stainless steel. Class II Jubilant Cadista Pharmaceuticals Inc.
Apr 1, 2014 PSYLLIUM FIBER, Laxative/Supplement, 100 Capsules, OTC. Manufactured By: Kon... Labeling: Label Error on Declared Strength; Listed active ingredient strength is inaccurate. Class III Konsyl Pharmaceuticals Inc
Jan 27, 2014 Suprax, Cefixime for Oral Suspension USP 500 mg/5 ml, 10mL (when reconstitute... Failed Impurities/Degradation Specifications: Product did not meet specification in total impurit... Class III Lupin Pharmaceuticals Inc.
Jan 27, 2014 Suprax, Cefixime for Oral Suspension USP, 500 mg/5 ml, 20 mL (when reconstit... Failed Impurities/Degradation Specifications: Product did not meet specification in total impurit... Class III Lupin Pharmaceuticals Inc.
Nov 1, 2013 PEGASPARGASE ONCASPAR Injection, 3750 International Units Per 5mL vial, Rx ON... Lack of Assurance of Sterility: Sigma-Tau PharmaSource, Inc. is conducting a voluntary recall of ... Class II Sigma-Tau Pharmaceuticals, Inc.
Sep 17, 2013 Quinapril Tablets USP, 5 mg, 90 count bottle, Rx only, Manufactured for: Lup... Failed Impurities/Degradation Specifications: During stability testing an unknown impurity was fo... Class II Lupin Pharmaceuticals Inc.
Sep 17, 2013 Quinapril Tablets USP, 10 mg, 90 count bottle, Rx only, Manufactured for: Lu... Failed Impurities/Degradation Specifications: During stability testing an unknown impurity was fo... Class II Lupin Pharmaceuticals Inc.
Feb 22, 2013 Ethambutol Hydrochloride Tablets USP, 400 mg, 100-count bottles, Rx only, Man... Failed Impurities/Degradation Specifications: This product is being recalled due to an out of spe... Class III Lupin Pharmaceuticals Inc.
Feb 11, 2013 Pantoprazole Sodium Delayed Release Tablets USP, 40 mg, 90 count bottles, Man... cGMP Deviations: Oral products were not manufactured in accordance with Good Manufacturing Practi... Class II Jubilant Cadista Pharmaceuticals Inc.
Jan 31, 2013 Suprax (cefixime for oral suspension) USP, 100 mg/5 mL, 50 mL bottles (when r... Discoloration; Product may not meet specifications for color description once reconstituted. Class III Lupin Pharmaceuticals Inc.

Frequently Asked Questions

When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.

The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.

Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.